Trials / Completed
CompletedNCT05269082
A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults
In Vitro Assessment of Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood From Patients at Increased Risk of Developing Hypersensitivity Reactions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to find out whether TAK-880 creates hypersensitivity reactions compared to Gammagard S/D by testing blood taken from participants who have a higher risk of becoming hypersensitive to immunoglobulin products. This study is about collecting data available in the participant's medical record. No study medicines will be provided to participants in this study. Each participant will fill out a study questionnaire during a routine doctor visit. Blood will be taken from participants who have a higher risk of developing hypersensitivity reactions to immunoglobulin products.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is a non-interventional study. |
Timeline
- Start date
- 2022-04-05
- Primary completion
- 2022-09-19
- Completion
- 2022-09-19
- First posted
- 2022-03-07
- Last updated
- 2022-09-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05269082. Inclusion in this directory is not an endorsement.